after days or weeks of treatment. Maintenance treatment Introduction is usually continued with oral or depot formulations for at least 1 year after the first episode. However, approxiSchizophrenia mately 75% of patients will relapse within 12 to 18 Schizophrenia normally begins in late adolescence or months of discontinuation of treatment [7, 8] . Recurrent early adulthood. It is a chronic disease, often severe and disease should therefore be treated indefinitely. disabling, and is characterised by acute episodes, with Many drugs are currently available for the oral varying periods of remission between these. Acute treatment of schizophrenia and related disorders. The episodes may present with positive symptoms including most notable differences between these are the incidence delusions, hallucinations, thought disorders, changing of adverse effects and cost. Adverse effects may be serious mood, and often catatonic phenomena. Patients with and irreversible, the most troublesome being extrapyramichronic disease may also have negative symptoms dal side-effects (EPS), including acute dystonia, akathisia, including lack of drive and initiative, social withdrawal parkinsonism, and tardive dyskinesia. Patients on longand blunting of emotional expression. There is a high term treatment and/or receiving high doses are thought mortality amongst schizophrenics and about 10% overall to be at highest risk of EPS. commit suicide [1, 2] .
The British National Formulary (BNF) classifies the Schizophrenia is common with an incidence of 10-70 drugs into three groups according to the pattern and per 100,000, a prevalence of 3-4 per 1000, and a lifetime frequency of adverse reactions: risk of 1% [3, 4] . Thus, at any time, there may be Group 1: chlorpromazine, methotrimeprazine, and promaupwards of about 110,000 sufferers in the UK, with zine; generally characterised by pronounced sedative perhaps 16,500 new cases each year. In 1994/95, there effects and moderate antimuscarinic and extrapyramidal were almost 25,000 hospital episodes for schizophrenia side-effects. and a further 23,000 for other affective disorders in Group 2: pericyazine, pipothiazine, and thioridazine; England [5] . Schizophrenia and allied disorders therefore generally characterised by moderate sedative effects, represent a very substantial disease burden for sufferers marked antimuscarinic effects, but fewer extrapyramidal and their families and carers, and a significant resource side-effects than Groups 1 or 3. commitment for health and social services.
Group 3: fluphenazine, perphenazine, prochlorperazine, and A number of factors may predispose to schizophrenia, trifluoperazine; generally characterised by fewer sedative including a possible genetic component, possible environeffects, fewer antimuscarinic effects, but more pronounced mental hazards ( particularly obstetric complications and extrapyramidal side-effects than Groups 1 and 2. maternal influenza), and the season of birth. The detailed Drugs of other chemical groups tend to resemble the pathophysiology of schizophrenia has not been deterphenothiazines of Group 3. They include the butyromined, but it may result from dopaminergic overactivity.
phenones (benperidol, droperidol, and haloperidol); Evidence for this includes: the antagonism of dopamine diphenylbutylpiperidines ( pimozide); thioxanthenes (flureceptors by antipsychotics both in vivo and in vitro; the penthixol and zuclopenthixol); substituted benzamides association of antipsychotic efficacy with antagonism of (sulpiride); oxypertine; and loxapine. D 2 -receptors; exacerbation of signs and symptoms by Antipsychotics also have a variety of adverse autonomic, dopamine agonists; and autopsy reports showing increased neuroendocrine, cardiac, ophthalmic, and haematologic D 2 -receptor densities in schizophrenics. Recent research effects. Rarely, neuroleptic malignant syndrome, a potenhas investigated whether dysfunction of other neurotially fatal complication, may develop [9] . transmitters leads to abnormal dopamine function; for Many patients with schizophrenia are deemed resistant example, clozapine has affinity for many receptors, or refractory, and either gain little benefit from standard including the subtypes D 4 , 5-HT 2 and 5-HT 3 [6] . treatment or cannot tolerate the extrapyramidal sideeffects of conventional antipsychotics. However, the clinical situation is difficult to define precisely. Thus, Current management options about 30% of patients (with acute episodes) in trials show only limited improvement. Operational definitions of Although psychosocial treatment, including counselling, education, and family interventions, is important, longtreatment-resistance vary, from failure to respond to two conventional antipsychotics given for 6 weeks, to more term drug treatment is the mainstay of management for schizophrenia in most patients. The first effective drugs, formal grading systems involving assessments over 1 week to 6 months [10] . In the UK, the number of patients the phenothiazines, have been available since the 1950s. Their antipsychotic effect manifests in two ways; control who could be classed as treatment-resistant might be around 33,000 to 44,000 (i.e., between 600 and 800 per of agitation and aggression, taking between a few minutes and a few hours, and alleviation of psychotic symptoms, million population).
A number of studies of antipsychotic utilisation have patients with acute exacerbations cannot be assumed to extend to maintenance treatment and vice versa. Similarly, been published. Among the concerns raised in a recent UK study was the frequent use of antipsychotics at higher efficacy and safety in patients with schizophrenia cannot be used to support use in allied conditions, such as than recommended doses [11] . Of 192 psychiatric inpatients studied 89% were receiving antipsychotics, 54% schizo-affective disorder, which have a different clinical course. of whom received depot preparations; 41% of those on treatment were prescribed two or more antipsychotics Assessment of negative symptoms: a specific, valid scale is needed (e.g., negative PANNS or Scale for Assessment concurrently. The mean dose was 1262 mg of chlorpromazine (CPZ) equivalents; almost half of patients were of Negative Symptoms (SANS)) but assessment of improvement remains difficult because: receiving more than the usual upper treatment limit of 1000 mg CPZ equivalents daily, though the number of $ Negative symptoms may be secondary to other causes, e.g., psychotic symptoms, depression, extrapyramidal patients receiving greater than 4000 mg CPZ equivalents daily had fallen since a similar audit in 1991 (3% vs 12%).
effects, hospitalisation. Thus, a favourable change in symptom scores does not, by itself, confirm a direct The authors stress the difficulties for clinicians in deciding what is a 'high' dose for a particular drug (and, by effect upon negative symptoms. $ Therapeutic effects on negative symptoms are expected implication, for any individual patient).
The last decade has seen the introduction of so-called to take more time to develop; the EMEA recommends that trials last at least 8 weeks (many published studies atypical antipsychotics including remoxipride, olanzapine, risperidone and sertindole, and also the re-introduction last 6 weeks or less). $ In an acute episode of schizophrenia, it is difficult to of the atypical agent clozapine in 1990. Remoxipride was withdrawn in 1993 due to reports of aplastic anaemia. distinguish negative symptoms from other phenomena. Therefore, results from trials in patients experiencing The newer agents are variously claimed to reduce the incidence and severity of adverse effects, to be superior acute episodes provide less direct evidence of effect on negative symptoms. in improving negative symptoms, and to be more effective in refractory patients. This report reviews their clinical
The interpretation and presentation of clinical trials is therefore not straightforward. For clozapine and risperiefficacy and safety and considers their place in therapy.
done, we have relied upon two systematic reviews. For other drugs, original trial data are mainly presented as it is commonly reported, as the mean change from baseline Clinical rating scales in the various clinical rating scales. Table 2 shows a summary of comparative trials reviewed. The clinical diagnosis and objective assessment of patients with schizophrenia is difficult in practice, not least because patients may be unable to give a reliable clinical Clinical efficacy and adverse effects of individual history necessary for an optimal assessment of their status. A number of rating scales have therefore been developed drugs for use both in clinical studies and in routine practice. In Clozapine addition to scales employed as measures of efficacy and safety, almost all clinical trials also used the Diagnostic Clozapine (ClozarilA, Sandoz) is a dibenzodiazepine and has dopamine, 5-HT, histamine and adrenergic receptor and Statistical Manual of Mental Disorders (DSM) criteria for schizophrenia. This provides a means for the uniform antagonist properties. It is licensed in the UK for patients resistant to, or intolerant of, other agents. diagnosis of psychiatric conditions, first developed by the American Psychiatric Association in 1952.
The UK Cochrane Collaboration has recently published a systematic review of clozapine vs typical neuroleptics in The European Medicines Evaluation Agency (EMEA) has recently published a detailed account of the issues schizophrenia in which the results of 27 controlled trials, 23 of which were less than 13 weeks duration, were and difficulties in assessing antipsychotics [12] . Its views, and those of psychiatrists generally, appear to be that assessed [13] . Key findings included: $ There were no significant differences in efficacy for clinical rating scales such as Brief Psychiatric Rating Scale (BPRS) and Positive and Negative Symptom Scale broad outcomes such as mortality, patient dissatisfaction, working ability or suitability for discharge (PANSS) ( Table 1) are appropriate and valid and that changes shown are likely to translate into clinical benefits from hospital at the end of the study. $ In the short term (generally, studies of less than 13 weeks for patients. However, the EMEA report also includes general advice on the interpretation of clinical trial results duration), patients on clozapine had fewer relapses (odds ratio (OR) 0.5, 95% CI 0.3-0.7, number needed to treat and guidance on the following points in particular: Extrapolation: efficacy and safety benefits from studies in (NNT) 17), and more frequent clinically-important Beasley 1997 [19] 431 Acute schizophrenia 6 olanzapine, haloperidol Tollefson, 1997 [20] 1996 Schizophrenia 6 olanzapine, haloperidol Zimbroff 1997 [22] 497 Schizophrenia 8 sertindole, haloperidol Peuskens 1997 [23] 201 Acute schizophrenia 6 quetiapine, chlorpromazine Arvanitis 1997 [24] 286 Acute schizophrenia 6 quetiapine, haloperidol Moller 1997 [25] 191 Acute schizophrenia 6 amisulpride, haloperidol Klieser 1995 [26] 59 Schizophrenia 4 clozapine, risperidone Tran 1997 [27] 339 Schizophrenia 28 olanzapine, risperidone improvement (OR 0.4, CI 0.2-0.7, NNT 5). In of the drug was conditional upon a stringent programme of white cell count monitoring being carried out (Clozaril treatment-resistant patients, there was no difference in relapse rate across four studies while in two short-term Patient Monitoring Scheme). The cost of these tests is included in the price of the drug. studies there was a better clinical response to clozapine compared with conventional antipsychotics (OR 0.14, A study has been published analysing the results of the monitoring scheme for the first year of the drug's CI 0.08-0.25, NNT 4). $ Dry mouth (OR 0.3, CI 0.2-0.4, NNT 6) and reintroduction in the US [14]. In 11,555 patients who received clozapine, the incidence of agranulocytosis after extrapyramidal effects (OR 0.4, CI 0.2-0.8, NNT 6) were less frequent with clozapine while increased 1, and 1.5 years of treatment, was 0.80% and 0.91% respectively. Most cases occurred within the first 3 salivation, increased temperature and troublesome drowsiness were more frequent with clozapine. months of treatment (84%). The risk increased with age, and was higher in women. However, clozapine causes agranulocytosis in between 0.05% and 2% of patients, substantially higher than with
In addition to bone marrow depression, seizures are reported to occur in 14% of those treated with high standard antipsychotics, and because of this increased risk it was withdrawn from use soon after its introduction in doses of clozapine (over 600 mg day −1 ; normal maintenance dose range 150-300 mg day −1 ). the 1970s. In 1989 a relaunch was approved but supply anticholinergic activity, an activity profile very similar to Risperidone that of clozapine. It is licensed for the treatment of all forms of schizophrenia. The published evidence for Risperidone (RisperdalA, Janssen) is a benzisoxazole derivative which combines potent 5-HT 2 and dopamine olanzapine, all of which originates from the clinical research department of the manufacturer, amounts to one receptor antagonism. It is licensed for the treatment of acute and chronic schizophrenia.
placebo-controlled study, three randomised double-blind comparative studies with haloperidol (all lasting 6 weeks) The NHS Centre for Reviews and Dissemination has recently published a meta-analysis of eleven randomised and a 28-week comparison with risperidone. In a study of 152 patients, those given olanzapine controlled trials of risperidone and conventional antipsychotics in a total of 2513 patients (range 35 to 1362) 10 mg day −1 had significantly better improvements in BPRS and PANSS scores than either placebo or [15] . Key findings included: $ Overall, the proportion of patients showing clinical olanzapine 1 mg day
, while olanzapine 1 mg day
was no better than placebo [17] . improvement (defined as a 20% reduction from baseline BPRS or PANSS scores) was higher for Two trials have compared three doses of olanzapine with haloperidol and placebo. risperidone (OR 1.27, CI 1.04-1.56, NNT 20) though the absolute difference was modest (57% In the North American study, 335 patients were treated for 6 weeks; the mean changes from baseline in vs 52%). $ Patients receiving risperidone were less likely to total BPRS scores for placebo, low, medium and high dose olanzapine and haloperidol (mean dose 16.4 mg require medication for extrapyramidal symptoms (22.9% vs 38.4%, OR 0.51, CI 0.41-0.63, NNT 7), daily) were −3.1, −6.7, −12.6, −15.2 and −12.9 respectively [18] . Thus, all active groups were superior though the incidence increased with higher doses (>8 mg ) of risperidone.
to placebo and haloperidol and olanzapine had similar efficacy. Only high-dose olanzapine (15 mg daily) was $ The overall drop-out rate was lower in the risperidonetreated patients (29.1% vs 32.9%, OR 0.75, CI significantly better than haloperidol in terms of the mean change in negative symptom (SANS) scores; the mean 0.61-0.94, NNT 20) though the drop-out rate due to adverse experiences or treatment inefficacy showed baseline and change for high-dose olanzapine were 13.4 and −4.1 respectively and 13.2 and −2.0 for haloperidol. no improvement. $ In one study where the Scale for the Assessment of Medium (but not low-or high-) dose olanzapine produced significantly less deterioration in two of three Negative Symptoms (SANS) was used to assess the change in negative symptoms, there was no significant extrapyramidal symptom scales. The mean change from baseline in extrapyramidal symptom scores (Simpsondifference between risperidone and haloperidol. Eight further studies used the negative PANSS rating; only Angus, Barnes and AIMS scales) was, respectively, −0.3, -0.3 and −0.8 for medium-dose olanzapine and 1.0, 0.4 one showed risperidone to be significantly better than conventional antipsychotics (haloperidol in this study). and −0.2 for haloperidol. There were no other significant differences in adverse reaction rates between olanzapine When the results of all eight studies are considered, the difference in changes in PANSS scores was −0.74 and haloperidol. In a similar study outside North America, 431 patients (CI −1.50-0.02) which almost reaches statistical significance ( P=0.058).
received 1 mg (fixed dose), 5, 10 or 15 mg (all ±2.5 mg ) olanzapine, haloperidol (mean dose 11.8 mg daily) or $ Weight gain and palpitations/tachycardia were significantly more common with risperidone (P<0.05). placebo for 6 weeks [19] . There were no significant differences in any efficacy outcome measure between The neuroleptic malignant syndrome (NMS) has been described during risperidone treatment [16] . Two patients, olanzapine and haloperidol. The mean changes in extrapyramidal symptom scores were significantly better both over 80 years of age, were originally treated with sulpiride (one was also taking trifluoperazine) and for olanzapine compared with haloperidol, though baseline scores were not reported. developed EPS. Sulpiride was stopped and both patients were commenced on risperidone 2 mg daily. One
Most recently, a large international study has been published in which 1996 patients in 174 centres were developed symptoms of NMS within 12 h of the first dose, and the other within 5 days of starting treatment.
randomised to receive either olanzapine or haloperidol for 6 weeks (each at 5 mg daily increasing to 20 mg daily Both patients recovered after withdrawal of risperidone.
if necessary) [20] . Overall, 60% of patients completed the trial; the proportion was significantly higher in those Olanzapine given olanzapine (66% vs 47%, P<0.001). The mean changes in most measures of primary efficacy were Olanzapine (ZyprexaA, Lilly) is a thienobenzodiazepine, and is a potent 5-HT 2 and dopamine antagonist, with significantly greater for olanzapine-treated patients though in all cases, the absolute difference was modest. For Amisulpride example, the mean difference in BPRS score in the olanzapine group was −10.9 compared with −7.9 with Amisulpride (SolianA, Lorex Synthelabo) has also been launched in the UK (November 1997), and is licensed haloperidol ( P<0.02) [22] . Sertindole was no Global Impression of Severity, CGI-S). Similarly there more effective than haloperidol for all measurements of was no significant difference in adverse events except for psychosis. There were significantly fewer extrapyramidal increased or excess salivation which was more frequent events with any dose of sertindole compared with with clozapine than with either dose of risperidone. haloperidol.
In a larger study, 339 patients (in 35 centres) with Many drugs, including antipsychotics and antidepressschizophrenia, schizophreniform disorder or schizoants, cause QT interval prolongation (>500 ms) and in affective disorder were randomised to olanzapine or placebo-controlled studies of sertindole, QT prolongation risperidone for 28 weeks [27] . One hundred and seventywas reported in 1.6% of patients ( personal communieight patients (52.5%) completed the trial (57.6% olanzapcation, Lundbeck, 1997) . The manufacturer recommends ine, mean dose 17.2 mg; 47.3% risperidone, mean dose that patients receiving sertindole have a minimum of four 7.2 mg: P=0.059 for difference in completion rate). The ECGs in the first 12 months of treatment. only significant differences in efficacy measures were that For other adverse effects, nasal congestion and reduced mean improvements in the PANSS depression item and ejaculatory volume (in men) were significantly more SANSS summary score were slightly, though statistically common with sertindole compared with placebo [22] .
significantly, better in the olanzapine group (Table 3) . In addition, significantly more patients in the olanzapine group achieved at least a 40% improvement in BPRS Quetiapine scores, though the absolute difference was modest (olanzapine 36.9% vs risperidone 26.7%, P=0.049). Using Quetiapine (SeroquelA, Zeneca) was launched in the UK in October 1997 and is licensed for the treatment of Kaplan-Meier survival curves, more olanzapine-treated patients maintained their response (time until >=20% schizophrenia. Three placebo-controlled trials have been published confirming its efficacy. Quetiapine has also worsening in PANSS total score and CGI-S >=3). The estimated percentage of patients maintaining their acute been compared in patients with acute exacerbations of schizophrenia with both chlorpromazine and haloperidol response at 28 weeks was 87.9% for olanzapine and 67.7% for risperidone. in studies lasting 6 weeks [23, 24] . No significant differences in efficacy between quetiapine and the The proportion of patients reporting any extrapyramidal event was significantly less for olanzapine (18.6% vs conventional drugs were found but there were significantly fewer, or less deterioration in, extrapyramidal 31.1%, P=0.022). Results from the rating scales used are not presented but analysis of Simpson-Angus scores was symptoms in the quetiapine groups. reported to show that fewer olanzapine patients experiOther considerations enced treatment-associated pseudoparkinsonism (12.5% vs 22.3%, P=0.034). Similarly, the proportion of patients Atypical agents are currently available for oral adminstration in tablet form only except for risperidone which is who developed treatment-associated akathisia, based on the Barnes Akathisia Scale was lower in the olanzapine also available as an oral liquid formulation. Conventional drugs are available in a wider variety of dose forms; for group (15.9% vs 27.3%, P=0.023). Finally, analysis of AIMS scores showed that the proportion of patients with example, haloperidol is available for oral administration in tablet, low-dose capsule or liquid form, and for dyskinetic symptoms was also lower for olanzapine (4.6% vs 10.7%, P=0.049). Amongst other adverse effects parenteral use as a conventional or depot injection. The absence of a depot form of atypical agents may be a reported by patients, weight gain was more common with olanzapine (mean increase 4.1 kg vs 2.3 kg, P= significant practical drawback. Treatment costs are up to 100 times greater than for 0.015), while nausea, amblyopia, increased salivation, suicide attempt, abnormal ejaculation, back pain, creatinconventional antipsychotics (Table 4) . For example, the annual cost of treatment with clozapine at 150 mg day
ine phosphokinase increases and urinary tract infection were all more common with risperidone. is about £1000 but there are, in addition, hidden costs, including those of time spent for weekly monitoring by Three smaller studies have also been published. There was no evidence of improvement in 10 patients who both patients and providers of care, and the costs of treatment of haematological toxicity. were resistant to clozapine treatment and who were switched to risperidone for 12 weeks [28] . In a randomised
In 1996, in England, there were 4.826 M primary care prescriptions dispensed for drugs used in psychosis and crossover study of 6 weeks treatment with clozapine and risperidone, there was no difference in efficacy as related disorders (BNF Section 4.2) at a total cost of £31.048 M, 1% and 0.8% respectively of total prescripmeasured by PANSS, but sleepiness and lack of alertness were more frequent with clozapine while insomnia and tions and cost [31] . The most commonly prescribed agents were thioridazine, chlorpromazine and haloperidol, restlessness were more frequent with risperidone [29] . In a similar but non-randomised small study, 13 patients accounting for 64% of prescriptions for non-depot antipsychotics. Risperidone accounted for only 3.3% of were treated with risperidone for 3 months; five of the six who did not respond showed improvement after prescriptions whereas it was the leading cost agent in 1996 (£10.8 M) accounting for 43% of the total cost of subsequent treatment with clozapine [30] .
oral antipsychotics. The number of patients receiving antipsychotic mediIndications other than schizophrenia and schizo-affective cation is difficult to estimate both because available data disorders represents primary care prescribing only and because many drugs are used (often in lower doses) for conditions Conventional antipsychotics are also commonly used, often in substantially lower doses, in other conditions other than schizophrenia. In addition, because of local variations in practice, no single estimate can be placed such as behaviour disturbance in the elderly. There is little published evidence for the use of atypical agents in on the number of patients who might be deemed appropriate for treatment with atypical antipsychotics and these circumstances and appropriately lower doses have not yet been determined. Atypical antipsychotics are the additional costs which might consequently be incurred. The cost implications for the NHS of a currently licensed in the UK for treatment of schizophrenia and related schizo-affective disorders.
wholesale change to atypical antipsychotics is substantial. Given this large cost differential, robust evidence of The atypical agents are also being studied in other neuropsychiatric disorders; for example, clozapine has cost-effectiveness would be of particular benefit in supporting prescribing decisions. Among the largest been investigated for the treatment of psychosis associated with Parkinson's disease.
potential economic benefits are reductions in hospital stay (especially in patients who are refractory to and/or prior to, and during, clozapine treatment were £36 604 and £32 836 respectively, a mean saving of £3768. intolerant of, and therefore not compliant with, existing treatments) and improved quality of life. A number of An economic comparison of risperidone and haloperidol has recently been published based upon sub-groups studies have attempted to address these points but many of these suffer from significant methodological shortfrom a large comparative trial and funded by the manufacturers of risperidone [35] . The study's methodcomings [32] . The studies reviewed below are among the more systematic assessments of cost-effectiveness of ology is complex. Sixty-five selected patients from the randomised controlled clinical trial were divided into clozapine and risperidone.
Two studies have examined the costs and benefits of three clusters (health states) according to PANSS and ESRS (Extrapyramidal Symptom Rating Scale) scores and clozapine for treatment-resistant schizophrenia in a UK setting [33, 34] .
each of these was assigned a health utility score. Patients who received risperidone had a mean utility score increase Using clinical trial data on 47 patients from a US trial of clozapine in treatment-resistant schizophrenia, Davies of 0.125 compared with an increase of 0.049 for haloperidol; when these were translated into qualityand Drummond constructed a clinical decision tree and calculated the likely costs and benefits in the UK practice adjusted life years (QALYs), there were incremental gains for risperidone treatment of 2.97 (4.84 vs 1.87) and 2.72 [33] . Despite some obvious (and conceded) flaws in the analysis, including the assumptions that hospital stays in (4.43 vs 1.71) for men and women respectively. The calculated cost per QALY was Can$5224 for haloperidol the US are the same as in the UK, the report shows that for patients treated with clozapine, there would be a net and Can$16 792 for risperidone but these estimates were derived simply from the change in health utility score lifetime increase in time spent with no or only mild disability of around 5.9 years compared with conventional and direct drug acquisition costs; no other direct or indirect costs, such as hospitalisation, were included. therapy. When the impact on all resources was taken into account the use of clozapine provided a yearly saving of £91 (£1333 per lifetime). In a series of sensitivity analyses, the use of clozapine was cost-saving or neutral.
Conclusions More recently, a further UK-based cost-effectiveness study has been carried out where 26 patients with
In terms of broad outcome measures, clozapine is as effective as, and may be more effective than, conventional treatment-resistant schizophrenia who attended a 'clozapine clinic' were followed prospectively until they had antipsychotics. It is effective in some patients refractory to conventional antipsychotics and it has a substantially undergone a mean of three years of clozapine treatment [34] . Benefits and costs were compared with those drawn lower incidence of EPS. Sedation, which can be troublesome, and increased salivation are more common from retrospective data prior to commencement of clozapine. Eighty-five per cent of patients showed a with clozapine. Clozapine is therefore a valuable option for patients who do not respond to treatment with clinically useful reponse to clozapine; the primary measure of cost-effectiveness, the ratio of quality-of-life score to conventional antipsychotics and/or those who experience, or cannot tolerate, extrapyramidal symptoms. However, total annual costs was 15.2 and 33.0 prior to, and during, clozapine therapy respectively. Total mean annual costs patient selection is important in view both of the need for regular blood count monitoring and because of olanzapine may provide a small additional benefit, though whether this observed effect is the result of a specific sedation.
Overall, risperidone is as effective as conventional action upon such symptoms or secondary to other effects is not clear. There is insufficient published evidence antipsychotics such as haloperidol. Systematic review of available evidence concluded that the additional effect, if about sertindole, quetiapine or amisulpride to determine their place in treatment. any, on negative symptoms was small. The incidence of extrapyramidal effects is significantly lower than with
The lack of a depot injectable form of atypical drugs may be a serious practical disadvantage in practice. conventional agents (but rises at higher doses and may be higher than with other atypical antipsychotics).
There is little evidence to support the use of atypical agents for indications other than schizophrenia and schizoOlanzapine is as effective as haloperidol. Olanzapine may be more effective than haloperidol for negative affective disorder but where conventional agents are commonly used such as behaviour disturbances in the symptoms. The incidence of extrapyramidal effects is significantly lower than with haloperidol.
elderly. This area is particularly complicated since doses are often considerably smaller than those used in younger There is as yet insufficient published evidence to assess the place in treatment of sertindole, quetiapine and patients with psychoses. Atypical agents are not currently licensed for these indications. amisulpride. All appear to be as effective as conventional antipsychotics and to have a significantly lower incidence Finally, there would appear to be no rationale for the co-prescribing of atypical and conventional antipsychotics; of extrapyramidal effects. Their effects on negative symptoms need further evaluation. Treatment with any additional benefit would be likely to be lost.
Co-prescribing of anticholinergics should not be necessary sertindole is complicated by the need for ECG monitoring.
Treatment with conventional antipsychotics, while with the atypical agents; careful review of therapy may be needed to ensure that this has not been overlooked. effective in improving acute symptoms and for preventing relapse, has several limitations. The atypical antipsychotics
Other atypical antipsychotics are in development and studies are continuing with currently available atypical represent an opportunity to address three of thesetreatment resistance, extrapyramidal effects and negative drugs. The management of schizophrenia seems likely to change further over the next decade with large clinical symptoms, upon which conventional drugs have only a modest effect.
and financial implications for health services. All atypical drugs are at least as effective as conventional antipsychotics and they have a significantly lower inci-
